ALEXANDER GLICK, M.D.
Medical Oncology Physician · SARASOTA, FL
Individual Active NPI 1598081911
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 1,735 | 422,281 | $24,852,173 | $9,605,459 | $7,648,765 |
| 2023 | 1,946 | 400,454 | $24,958,135 | $8,980,743 | $7,134,204 |
| 2022 | 2,110 | 372,474 | $26,020,317 | $9,708,865 | $7,793,577 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 59,670 | $0 | $0 |
| J9299 | Injection, nivolumab, 1 mg | 28,400 | $31 | $25 |
| J9271 | Injection, pembrolizumab, 1 mg | 23,000 | $56 | $45 |
| J9025 | Injection, azacitidine, 1 mg | 17,800 | $0 | $0 |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 16,200 | $49 | $39 |
| J1756 | Injection, iron sucrose, 1 mg | 14,300 | $0 | $0 |
| J0897 | Injection, denosumab, 1 mg | 13,020 | $26 | $21 |
| Q5110 | Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 12,720 | $0 | $0 |
| J9267 | Injection, paclitaxel, 1 mg | 10,229 | $0 | $0 |
| J9173 | Injection, durvalumab, 10 mg | 9,052 | $80 | $64 |
| J2182 | Injection, mepolizumab, 1 mg | 8,700 | $30 | $24 |
| J1434 | Injection, fosaprepitant (focinvez), 1 mg | 8,550 | $3 | $2 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Medical Oncology Physician | 207RX0202X | ✓ | ME128071 | FL |
| Hematology (Internal Medicine) Physician | 207RH0000X | ME128071 | FL |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Medical Oncology Physician providers in Florida
- NPI 1134388689
- NPI 1831624428
- NPI 1841637436
- NPI 1235112053
- NPI 1124155569
- NPI 1003031212
- NPI 1093891673
- NPI 1104817063
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.